AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit
VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--Dec 17, 2018--AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018. The R&D Tax Credit Incentive program provides a cash rebate to support companies in Australia conducting research and development projects. Projects undertaken by AVITA Medical qualifying for the rebate include the development of its RECELL® Autologous Cell Harvesting Device (RECELL® System), as well as expanded research and development related to the RECELL System and the Company’s broader regenerative medicine platform.
“The non-dilutive financing provided by the R&D tax credit has greatly assisted our development of the RECELL System and we appreciate the ongoing support of the Australian government,” said Dr. Michael Perry, Chief Executive Officer. “As we close out 2018, we look forward to the next major milestone in AVITA’s progression, the early January 2019 U.S. market launch of RECELL for the treatment of thermal burns.”
ABOUT AVITA MEDICAL LIMITED
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION™ (RES™), an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.
AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System produces Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 7,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE – RECELL® Autologous Cell Harvesting Device for a full description of important safety information including contraindications, warnings, and precautions.
In international markets outside of Europe, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications, including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia, CFDA-cleared in China, and received CE-mark approval in Europe.
To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181217005902/en/
Phone: +61 (0)3 9620 3333
Mobile: +61 (0)407 162 530
email@example.comAVITA Medical Ltd
Dale A. Sander
Chief Financial Officer
KEYWORD: AUSTRALIA UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA AUSTRALIA/OCEANIA CALIFORNIA
INDUSTRY KEYWORD: STEM CELLS HEALTH BIOTECHNOLOGY HOSPITALS MEDICAL DEVICES GENERAL HEALTH
SOURCE: AVITA Medical Ltd
Copyright Business Wire 2018.
PUB: 12/17/2018 10:49 PM/DISC: 12/17/2018 10:49 PM